About Dr. Zhuang Rongyuan
Dr. Zhuang Rongyuan (庄荣源) is a senior medical oncologist at Huashan Hospital, Fudan University, specializing in the systemic treatment of breast cancer. With deep expertise in hormone receptor-positive, HER2-positive, and triple-negative breast cancer, Dr. Zhuang provides individualized, biomarker-driven treatment plans that integrate the latest advances in targeted therapy, immunotherapy, and endocrine therapy for patients at all stages of disease.
Dr. Zhuang is known for her patient-centered approach, her ability to navigate complex multi-line treatment scenarios, and her expertise in managing breast cancer in younger women, pregnancy-associated breast cancer, and male breast cancer — conditions that require specialized knowledge and careful individualization of systemic therapy. Her practice integrates seamlessly with Huashan's breast surgery and radiation oncology teams to provide comprehensive multidisciplinary breast cancer care.
Hospital Affiliation
Huashan Hospital, Fudan University is consistently ranked among China's top hospitals. Its breast cancer program brings together medical oncology, breast surgery, radiation oncology, plastic and reconstructive surgery, and genetic counseling under a unified multidisciplinary framework. The department has access to comprehensive molecular profiling including Oncotype DX, BRCA1/2 germline testing, NGS-based tumor profiling, and HER2 FISH testing — enabling precise treatment selection for every patient.
Clinical Expertise
- Hormone receptor-positive (HR+) breast cancer — CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib); aromatase inhibitors; fulvestrant; PI3K/AKT/mTOR pathway inhibitors (alpelisib, everolimus)
- HER2-positive breast cancer — trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan (T-DXd); neoadjuvant and adjuvant HER2-targeted regimens
- Triple-negative breast cancer (TNBC) — immunotherapy (pembrolizumab); PARP inhibitors (olaparib, niraparib) for BRCA-mutant TNBC; sacituzumab govitecan; neoadjuvant chemotherapy optimization
- Metastatic breast cancer — multi-line treatment planning; bone, liver, lung, and brain metastasis management; quality of life optimization
- Neoadjuvant chemotherapy — pathological complete response optimization; post-neoadjuvant therapy escalation/de-escalation
- Breast cancer in young women — fertility preservation coordination; ovarian suppression; pregnancy-associated breast cancer management
- Hereditary breast cancer — BRCA1/2 and other germline mutation management; risk-reduction strategies; family counseling coordination
- Male breast cancer — systemic therapy individualization; hormonal therapy; genetic counseling
- Bone health in breast cancer — bisphosphonates, denosumab; osteoporosis prevention during endocrine therapy
- Clinical trial access — phase I–III trials for novel targeted agents and antibody-drug conjugates in breast cancer
Academic & Research Contributions
Dr. Zhuang Rongyuan has contributed to peer-reviewed publications in leading oncology journals and is an active member of the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Committee. Her research focuses on the optimization of endocrine therapy sequencing in HR+ metastatic breast cancer, the management of CDK4/6 inhibitor resistance, and the clinical outcomes of HER2-targeted therapy in Chinese breast cancer patients.
She has participated as a sub-investigator in multiple multicenter clinical trials evaluating novel targeted agents and antibody-drug conjugates in breast cancer, and is a regular attendee and presenter at CSCO, ASCO, and the San Antonio Breast Cancer Symposium (SABCS). Her clinical work contributes to Huashan's growing reputation as a center of excellence for breast cancer systemic therapy in Shanghai.
Why International Patients Choose Dr. Zhuang
International patients seek Dr. Zhuang's expertise for second opinions on breast cancer treatment plans, access to novel agents and clinical trials, and management of metastatic or treatment-resistant disease. Women facing complex decisions about neoadjuvant chemotherapy, CDK4/6 inhibitor selection, or post-progression therapy in metastatic disease particularly benefit from her depth of experience and individualized approach.
The cost advantage is significant: HER2-targeted therapy, CDK4/6 inhibitors, and PARP inhibitors are available at Huashan at substantially lower cost than in the United States or Europe, making Shanghai an increasingly attractive destination for patients managing long-term breast cancer treatment. CMCS coordinates all aspects of the visit, from medical record translation to treatment coordination and remote follow-up support.
What to Expect at Your Consultation
Consultations with Dr. Zhuang begin with a comprehensive review of pathology, receptor status, molecular profiling, imaging, and prior treatment history. CMCS will arrange certified translation of all records in advance. Dr. Zhuang will provide a detailed treatment plan including systemic therapy options, clinical trial eligibility, and supportive care recommendations — all summarized in English for your home oncologist or breast cancer team.
Frequently Asked Questions
Can Dr. Zhuang provide a second opinion on my breast cancer treatment plan?
Yes. Second-opinion consultations are a core part of the international patient practice at Huashan. CMCS will arrange translation of your pathology and imaging reports and coordinate a comprehensive review appointment.
Are CDK4/6 inhibitors and T-DXd available at Huashan?
Yes. Huashan Hospital has access to all major approved targeted agents for breast cancer, including CDK4/6 inhibitors, trastuzumab deruxtecan (T-DXd), sacituzumab govitecan, and PARP inhibitors, at significantly lower cost than in Western markets.
Can I continue treatment at home after my consultation?
Yes. Dr. Zhuang will provide a detailed management plan that your home oncologist can implement, including drug protocols, monitoring schedules, and follow-up imaging recommendations.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking breast cancer care with Dr. Zhuang Rongyuan at Huashan Hospital, including priority appointment scheduling, certified medical translation, molecular profiling coordination, and post-consultation follow-up. Contact us at contract@medicalsh.com, or visit medicalsh.com.
0 comentarios